Ischemic Stroke Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ischemic Stroke Pipeline Report
• Over 50+ Ischemic Stroke companies are evaluating 55+ Ischemic Stroke pipeline therapies in various stages of development, and their anticipated acceptance in the Ischemic Stroke market would significantly increase market revenue.
• The leading Ischemic Stroke Companies working in the market include Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, Shijiazhuang Yiling Pharmaceutical Co. Ltd, and others.
• Promising Ischemic Stroke Pipeline Therapies in the various stages of development include MultiStem, Elezanumab, LT3001, AP-188, 3K3A-APC, NIN-S119, RNS60, PP 007, Glenzocimab, SB-623, AVLX-144, BIIB 131, Conestat alfa, NCS-01, Nerinetide, UMC119-06, SY-007, Edaravone, TB006, Neu2000, Balovaptan, DM 199, ApTOLL, BMS-986177, NanO2, Tenecteplase, SIM1910-09, UMSC01, Prourokinase recombinant, Sovateltide, and others.
• April 2024: Shionogi announced a study of Phase 2 clinical trials for Redasemtide. The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS).
• March 2024: BrainQ Technologies Ltd.- The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)

Request a sample and discover the recent advances in Ischemic Stroke Treatment Drugs @ Ischemic Stroke Pipeline Outlook Report- https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Ischemic Stroke pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Ischemic Stroke NDA approvals (if any), and product development activities comprising the technology, Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Ischemic Stroke Overview
Stroke is a leading cause of death and disability worldwide and can be broadly classified into ischaemic stroke and haemorrhagic stroke, the latter of which includes intracerebral haemorrhage and subarachnoid haemorrhage. Ischaemic stroke is defined as infarction of the brain, spinal cord or retina1 and represents ~71% of all strokes globally. Advances in brain imaging have shifted the definition of ischaemic stroke from a largely clinical determination to a tissue-based classification.

Find out more about Ischemic Stroke Therapeutics Assessment @ Ischemic Stroke Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ischemic Stroke Emerging Drugs Profile

• 3K3A-APC: ZZ Biotech
3K3A-APC, is a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. 3K3A-APC was designed to enhance the cytoprotective and anti-inflammatory activities of APC while greatly reducing its anti-coagulant activity. APC is a protease possessing two distinct functions: 1) anticoagulant properties mediated by proteolysis of coagulation factors Va and VIIIa, and 2) cytoprotective effects including anti-apoptotic effects, anti-inflammatory effects, and endothelial barrier stabilization. ZZ Biotech has completed RHAPSODY, a multicenter Phase II clinical trial of its experimental drug, 3K3A-APC and is in Phase III for the treatment of patients suffering from acute ischemic stroke. This study was supported by the National Institutes of Health through a pair of NeuroNEXT grants.
 
• BMS-986177: Bristol-Myers Squibb
BMS-986177 (Factor XIa) is an investigational anticoagulant compound. Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway. A small study of Hemophilia C patients showed a lower risk of stroke. Currently the product is in Phase III stage of development for treatment of Ischemic Stroke and Transient Ischemic Attack (TIA).

• XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
XY03 EA, is an investigational drug being developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. XY03-EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03-EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose-dependent way. Mechanistically, XY03-EA inhibited ROS-dependent autophagy activation and thereby protected the PC-12 cells from the autophagic cell death induced by OGD/R. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.

• NONO-42: NoNO Inc.
NoNO-42 is a nerinetide analog intended for use in people experiencing an acute ischemic stroke with or without thrombolytics. Of the 650,000 people experiencing an acute ischemic stroke treated annually in US hospitals, approximately 10% receive a thrombolytic, which may reduce the applicability of nerinetide. Compatibility of NoNO-42 with thrombolytics broadens the availability neuroprotection and neurorestoration to all hospital treated strokes. Currently, the drug is in Phase I stage of its development for the treatment of acute ischemic stroke.

Ischemic Stroke Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Ischemic Stroke. The companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, ZZ Biotech.

DelveInsight's Ischemic Stroke pipeline report covers around 55+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Ischemic Stroke Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging Ischemic Stroke Pipeline Therapies @ Ischemic Stroke Clinical Trials Assessment- https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Ischemic Stroke Pipeline Report
• Coverage- Global
• Ischemic Stroke Companies- Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, Shijiazhuang Yiling Pharmaceutical Co. Ltd, and others.
• Ischemic Stroke Pipeline Therapies- MultiStem, Elezanumab, LT3001, AP-188, 3K3A-APC, NIN-S119, RNS60, PP 007, Glenzocimab, SB-623, AVLX-144, BIIB 131, Conestat alfa, NCS-01, Nerinetide, UMC119-06, SY-007, Edaravone, TB006, Neu2000, Balovaptan, DM 199, ApTOLL, BMS-986177, NanO2, Tenecteplase, SIM1910-09, UMSC01, Prourokinase recombinant, Sovateltide, and others.
• Ischemic Stroke Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ischemic Stroke Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new drugs for Ischemic Stroke Treatment, Visit @ Ischemic Stroke Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Ischemic Stroke: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ischemic Stroke- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. 3K3A-APC: ZZ Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NONO-42: NoNO Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ischemic Stroke Key Companies
21. Ischemic Stroke Key Products
22. Ischemic Stroke- Unmet Needs
23. Ischemic Stroke- Market Drivers and Barriers
24. Ischemic Stroke- Future Perspectives and Conclusion
25. Ischemic Stroke Analyst Views
26. Ischemic Stroke Key Companies
27. Appendix

For further information on the Ischemic Stroke Pipeline therapeutics, reach out to Ischemic Stroke Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.